Table 4.
Healthy Controls | AD group | P-valuea | P-valueb | |
---|---|---|---|---|
ADAS-Cog | ||||
Improved | 1 (2%) | 0 | < 0.001 | < 0.001 |
Unchanged | 45 (92%) | 35 (16%) | ||
Worsened | 3 (6%) | 178 (84%) | ||
MMSE | ||||
Improved | 1 (2%) | 3 (1%) | < 0.001 | < 0.001 |
Unchanged | 45 (92%) | 25 (11%) | ||
Worsened | 3 (6%) | 191 (87%) | ||
DAD | ||||
Improved | 0 | 20 (9%) | < 0.001 | < 0.001 |
Unchanged | 46 (94%) | 12 (5%) | ||
Worsened | 3 (6%) | 187 (85%) | ||
DS | ||||
Improved | 2 (4%) | 11 (5%) | < 0.001 | < 0.001 |
Unchanged | 45 (92%) | 22 (10%) | ||
Worsened | 2 (4%) | 186 (85%) | ||
NPI | ||||
Improved | 1 (2%) | 55 (25%) | < 0.001 | < 0.001 |
Unchanged | 46 (94%) | 60 (27%) | ||
Worsened | 2 (4%) | 104 (47%) | ||
NPI Caregiver | ||||
Improved | 0 | 44 (20%) | < 0.001 | 0.005 |
Unchanged | 44 (90%) | 82 (37%) | ||
Worsened | 5 (10%) | 93 (42%) | ||
CDR-SB | ||||
Improved | 0 | 22 (10%) | < 0.001 | < 0.001 |
Unchanged | 47 (96%) | 16 (7%) | ||
Worsened | 2 (4%) | 181 (83%) | ||
NTB-Memory | ||||
Improved | 3 (6%) | 0 | < 0.001 | < 0.001 |
Unchanged | 42 (86%) | 73 (34%) | ||
Worsened | 4 (8%) | 143 (66%) | ||
NTB-Executive Function | ||||
Improved | 2 (4%) | 0 | < 0.001 | 0.016 |
Unchanged | 44 (90%) | 90 (42%) | ||
Worsened | 3 (6%) | 126 (58%) | ||
Total NTB | ||||
Improved | 4 (8%) | 1 (< 1%) | < 0.001 | 0.003 |
Unchanged | 42 (86%) | 60 (28%) | ||
Worsened | 3 (6%) | 155 (72%) |
Chi-squared tests comparing the change from baseline to 78 weeks between AD participants and healthy controls;
Difference between groups over time using GEE.